

Mary & Dick Allen **Diabetes Center**

We believe every child and adult with diabetes deserves advanced, comprehensive, and compassionate care. Your generous support makes this life-changing work possible, positively impacting the lives of our patients and the community every day.

Impact by the Numbers

80%

percentage of patients with type 1 diabetes using continuous glucose monitors and/or insulin pumps to improve diabetes control



8.2% → 7%



within six months, new patients show significant improvement in HbA1c levels, reducing the risk of diabetes-related complications



new clinical trials started since 2023



support group gatherings held in 2023 for type 1 diabetes, type 2 diabetes, and pregnancy



percentile in patient experience

Recent Wins Thanks to Philanthropy

- Dr. Diana Zhao joined the Mary & Dick Allen Diabetes Center and Metabolism & Weight Management Center at Hoag, bringing extensive expertise in endocrinology and a commitment to personalized patient care. Dr. Zhao's work will expand the center's capacity to treat patients and focus on a comprehensive combination therapy approach.
- The center implemented an in-clinic, Al-based eye screening protocol that transforms diabetic retinopathy (DR) detection by identifying the condition before symptoms appear, allowing for prompt treatment and the preservation of eyesight. DR is the leading cause of blindness worldwide for working-age adults.
- In September, the center launched Revitalize, a dynamic, insurance-covered weight management program. It combines tailored support from clinical professionals with physician oversight to help patients achieve their health goals.

Renowned & Recognized

Hoag is proud to be the highest-ranked Orange County hospital for Diabetes & Endocrinology according to *U.S. News & World Report.*





Dr. David Ahn, Dr. Kris V. Iyer Endowed Chair in Diabetes Care, was invited to present at the 2024 American Diabetes Association's Clinical Update Conference, where he shared his expertise nationally as a thought leader in diabetes technology.

Hoag joins Stanford, Johns Hopkins, and Harvard as one of 12 clinical sites across the country participating in the Diamyd[®] beta cell preservation. This groundbreaking trial started screening patients in May 2024 and is evaluating a novel medication that aims to delay the progression of type 1 diabetes.

Grateful Patient Spotlight:

Support Group Empowers a Young Diabetic to Take Control of Her Health



"At 31, I was diagnosed with type 1 diabetes, which was a shock since I'm very fit and thought I couldn't be diabetic. I received prescriptions but had no idea what they were for or their importance. It wasn't until I found resources and support through the Herbert Program at Hoag that I knew what to do. This group has given me the confidence to vocalize my needs, ask for help, and be myself. It's been phenomenal."

Destiny
Participant, Herbert Program for
Young Adults with Type 1 Diabetes

For more information, contact Camille Schwan, senior director of development, Hoag Hospital Foundation, at (949) 764-7244 or Camille.Schwan@hoag.org.

hoag Hospital Foundation